| Name | Title | Contact Details |
|---|
Healthcare South Pc is a Pembroke, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gullapalli and Associates is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CareerSource Heartland is a not-for-profit corporation that operates as a demand-driven and business focused public-private partnership. Through oversight provided by the local elected officials from DeSoto, Hardee, and Highlands counties, our Board of Directors offer workforce development related growth opportunities to Business Customers and Job Seekers throughout our Tri-County service delivery area. As one of twenty-four Regional Workforce Boards in Florida, we oversee the workforce and talent development activities in the tri-county region, collaborating with numerous private and public sector organizations and businesses to enhance the local economy. Our Board has a diversified membership with a majority of the members from the private (business) sector. The Board also includes representatives from secondary and post-secondary education institutions, Economic Development commissions, and community based organizations.
Cypress Palms welcomes you to our unique senior living community that offers everything you need and want in Assisted Living. From vibrant social programs and amenities that delight and entertain our residents to exceptional dining, abundant services and compassionate care; a great lifestyle tailored to your needs awaits you here.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.